Next-Generation Trispecific Nanobody Targeting ADAMTS5 and MMP13 for Osteoarthritis Therapy

VHH-P716 is a humanized nanobody therapeutic candidate developed to target ADAM metallopeptidase with thrombospondin type 1 motif 5 (ADAMTS5) and matrix metallopeptidase 13 (MMP13). Currently in the Biological Testing stage, VHH-P716 represents an innovative approach for the treatment of osteoarthritis. By simultaneously addressing two key proteases implicated in cartilage degradation, this molecule holds significant potential for disease modification and symptomatic relief in osteoarthritis, a condition with considerable unmet medical needs.

Licensing Opportunity

VHH-P716 is available for out-licensing and collaborative development opportunities. We welcome inquiries from partners seeking innovative nanobody-based therapeutics in osteoarthritis and related indications.

Development Phase

Modality

VHH-P716 is a tetravalent trispecific polypeptide engineered from single variable domains against MMP13, ADAMTS5, and aggrecan—genetically linked via flexible 35GS linkers. As a nanobody-based modality, it leverages the small molecular weight, high stability, and exceptional tissue penetration characteristic of single-domain antibodies. This allows for enhanced access to joint cartilage and inflamed tissues in osteoarthritis, potentially increasing therapeutic efficacy. The modular structure also presents design flexibility for multi-target engagement in complex disease microenvironments.

Target

ADAMTS5 and MMP13 are matrix-degrading proteases central to the pathogenesis of osteoarthritis. Both ADAMTS5 and MMP13 are enzymes involved in the breakdown of extracellular matrix components in cartilage, leading to joint degeneration. ADAMTS5 is predominantly expressed in chondrocytes and synovial tissues of affected joints, while MMP13 is mainly found in chondrocytes and osteoarthritic cartilage. Overactivity of ADAMTS5 and MMP13 accelerates cartilage loss and joint inflammation. As validated targets in osteoarthritis research, selective inhibition of ADAMTS5 and MMP13 is anticipated to slow or halt disease progression. VHH-P716’s trispecific design directly targets both ADAMTS5 and MMP13, representing a highly strategic therapeutic asset for disease modification.

Mechanism of Action

VHH-P716 is designed to bind and inhibit the enzymatic activity of both ADAMTS5 and MMP13, two primary mediators of cartilage matrix degradation in osteoarthritis. By engaging these proteases, VHH-P716 disrupts the catabolic processes responsible for proteoglycan and collagen breakdown, thereby potentially preserving cartilage integrity and reducing joint inflammation. The nanobody format further allows for the generation of next-generation constructs, including bispecifics, trispecifics, or conjugates with other modalities such as antibody-drug conjugates, enabling broader disease applications. This multifaceted approach positions VHH-P716 as a competitive candidate for osteoarthritis therapy and beyond.

Osteoarthritis

Osteoarthritis is a prevalent, progressive joint disorder characterized by cartilage degeneration, chronic pain, and impaired mobility, affecting millions globally. It represents a leading cause of disability, especially among the aging population. Current treatments focus primarily on symptomatic relief, such as non-steroidal anti-inflammatory drugs, intra-articular corticosteroids, and physical therapy. Surgical interventions, including joint replacement, are reserved for advanced cases. However, there remains a lack of disease-modifying therapies capable of targeting the underlying molecular mechanisms driving cartilage degradation. The need for disease-modifying osteoarthritis drugs (DMOADs) is acute, as existing therapies do not halt structural progression or adequately address chronic inflammation. By simultaneously inhibiting two key proteases, VHH-P716 may offer a transformative approach to osteoarthritis management, with the potential to alter disease progression and improve long-term patient outcomes.